What does this research mean for the field?

Philadelphia-negative myeloproliferative neoplasms are driven by complex immunological dysfunction and chronic inflammatory dysregulation, and targeting these microenvironmental mechanisms is essential for developing novel precision treatments that overcome the limitations of current JAK inhibitors. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

August 23, 2026CancersOpen Access

Inflammatory and Immune Microenvironment in Myeloproliferative Neoplasms: Pathogenic Mechanisms and Therapeutic Opportunities

View Full Paper

Ask AI

Bookmark

Authors

FKFaride kaikavoosnejadKashan University of Medical Sciences AKAli KeyhaniKashan University of Medical Sciences SMSeyed Koosha MoosaviUniversità Cattolica del Sacro Cuore

Discussion

Member takes

Implication

Review uncovers inflammatory mechanisms and immune evasion in Philadelphia-negative myeloproliferative neoplasms, indicating the necessity of microenvironment-targeted precision therapies.

Key Points

To examine the pathogenic mechanisms of chronic inflammation and immune dysfunction in Philadelphia-negative myeloproliferative neoplasms and evaluate emerging therapeutic approaches targeting the tumor microenvironment.
Synthesized molecular and clinical evidence regarding somatic mutations in JAK2, CALR, and MPL genes that activate JAK–STAT and NF-κB signaling pathways.
Assessed microenvironmental alterations, immune cell exhaustion profiles, and clinical trial outcomes for FDA-approved JAK1/JAK2 inhibitors.
Driver mutations induce a chronic inflammatory cascade mediated by pro-inflammatory cytokines and reactive oxygen species, driving bone marrow fibrosis, splenomegaly, vascular niche remodeling, thrombosis, and secondary leukemic transformation.
The disease microenvironment induces profound immune evasion marked by progressive lymphopenia, T-cell and B-cell exhaustion, Natural Killer cell maturation arrest, and expansion of myeloid-derived suppressor cells.
Current FDA-approved JAK1/JAK2 inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib) provide symptom relief, reduce splenomegaly, and confer survival benefits, but they fail to eradicate malignant clones or prevent long-term disease progression.

Cite This Study

kaikavoosnejad et al. (2026) studied this question.

synapsesocial.com/papers/6a8aadd57677a34114446498 https://doi.org/10.3390/cancers18162718

View Full Paper

Ask AI

Bookmark

August 23, 2026CancersOpen Access

Inflammatory and Immune Microenvironment in Myeloproliferative Neoplasms: Pathogenic Mechanisms and Therapeutic Opportunities

View Full Paper

Ask AI

Bookmark

Authors

FKFaride kaikavoosnejadKashan University of Medical Sciences AKAli KeyhaniKashan University of Medical Sciences SMSeyed Koosha MoosaviUniversità Cattolica del Sacro Cuore

Discussion

Member takes

Implication

Review uncovers inflammatory mechanisms and immune evasion in Philadelphia-negative myeloproliferative neoplasms, indicating the necessity of microenvironment-targeted precision therapies.

Key Points

To examine the pathogenic mechanisms of chronic inflammation and immune dysfunction in Philadelphia-negative myeloproliferative neoplasms and evaluate emerging therapeutic approaches targeting the tumor microenvironment.
Synthesized molecular and clinical evidence regarding somatic mutations in JAK2, CALR, and MPL genes that activate JAK–STAT and NF-κB signaling pathways.
Assessed microenvironmental alterations, immune cell exhaustion profiles, and clinical trial outcomes for FDA-approved JAK1/JAK2 inhibitors.
Driver mutations induce a chronic inflammatory cascade mediated by pro-inflammatory cytokines and reactive oxygen species, driving bone marrow fibrosis, splenomegaly, vascular niche remodeling, thrombosis, and secondary leukemic transformation.
The disease microenvironment induces profound immune evasion marked by progressive lymphopenia, T-cell and B-cell exhaustion, Natural Killer cell maturation arrest, and expansion of myeloid-derived suppressor cells.
Current FDA-approved JAK1/JAK2 inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib) provide symptom relief, reduce splenomegaly, and confer survival benefits, but they fail to eradicate malignant clones or prevent long-term disease progression.

Cite This Study

kaikavoosnejad et al. (2026) studied this question.

synapsesocial.com/papers/6a8aadd57677a34114446498 https://doi.org/10.3390/cancers18162718

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark